JCAD, a new potential therapeutic target in cholestatic liver disease

키워드

참고문헌 (10)

1. Lindor KD, "Primary biliary cholangitis : 2018 Practice guidance from the American Association for the Study of Liver Diseases", Hepatology, 69, pp.394~419 (2019)
2. European Association for the Study of the Liver, "EASL clinical practice guidelines : The diagnosis and management of patients with primary biliary cholangitis", J Hepatol, 67, pp.145~172 (2017)
3. Tanaka A, "Current understanding of primary biliary cholangitis", Clin Mol Hepatol, 27, pp.1~21 (2021)
4. Mayo MJ, "Mechanisms and molecules : What are the treatment targets for primary biliary cholangitis?", Hepatology, 76, pp.518~531 (2022)
5. Zhao Y, "Primary biliary cholangitis : molecular pathogenesis perspectives and therapeutic potential of natural products", Front Immunol, 14, pp.1164202~ (2023)
6. Guzik TJ, "JCAD : a new GWAS target to reduce residual cardiovascular risk?", Eur Heart J, 44, pp.1834~1836 (2023)
7. Jones PD, "JCAD, a gene at the 10p11 coronary artery disease locus, regulates hippo signaling in endothelial cells", Arterioscler Thromb Vasc Biol, 38, pp.1711~1722 (2018)
8. Ye J, "JCAD promotes progression of nonalcoholic steatohepatitis to liver cancer by inhibiting LATS2 kinase activity", Cancer Res, 77, pp.5287~5300 (2017)
9. Xie L, "JCAD deficiency attenuates activation of hepatic stellate cells and cholestatic fibrosis", Clin Mol Hepatol, 30, pp.206~224 (2024)
10. Heo NY, "Epidemiology and updated management for autoimmune liver disease", Clin Mol Hepatol, 29, pp.194~196 (2023)

관련 논문AI추천